Across TCGA pan-cancer cohorts, LEUTX Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LEUTX data layer compared with 10 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher LEUTX Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LEUTX expression acts as an unfavorable survival marker.

MESO and UCEC are the cancer types where LEUTX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	II,III,IV	0.039	0.407	<.001	12	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: LEUTX tumor-vs-normal RNA expression · all LEUTX data types